These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

822 related items for PubMed ID: 11487509

  • 1. Direct effect of an acyl-CoA:cholesterol acyltransferase inhibitor, F-1394, on atherosclerosis in apolipoprotein E and low density lipoprotein receptor double knockout mice.
    Chiwata T, Aragane K, Fujinami K, Kojima K, Ishibashi S, Yamada N, Kusunoki J.
    Br J Pharmacol; 2001 Aug; 133(7):1005-12. PubMed ID: 11487509
    [Abstract] [Full Text] [Related]

  • 2. Acyl-CoA:cholesterol acyltransferase inhibition reduces atherosclerosis in apolipoprotein E-deficient mice.
    Kusunoki J, Hansoty DK, Aragane K, Fallon JT, Badimon JJ, Fisher EA.
    Circulation; 2001 May 29; 103(21):2604-9. PubMed ID: 11382731
    [Abstract] [Full Text] [Related]

  • 3. Acyl-coenzymeA (CoA):cholesterol acyltransferase inhibition in rat and human aortic smooth muscle cells is nontoxic and retards foam cell formation.
    Rong JX, Kusunoki J, Oelkers P, Sturley SL, Fisher EA.
    Arterioscler Thromb Vasc Biol; 2005 Jan 29; 25(1):122-7. PubMed ID: 15499046
    [Abstract] [Full Text] [Related]

  • 4. Urotensin II receptor knockout mice on an ApoE knockout background fed a high-fat diet exhibit an enhanced hyperlipidemic and atherosclerotic phenotype.
    Bousette N, D'Orleans-Juste P, Kiss RS, You Z, Genest J, Al-Ramli W, Qureshi ST, Gramolini A, Behm D, Ohlstein EH, Harrison SM, Douglas SA, Giaid A.
    Circ Res; 2009 Sep 25; 105(7):686-95, 19 p following 695. PubMed ID: 19696412
    [Abstract] [Full Text] [Related]

  • 5. Chronic urotensin II infusion enhances macrophage foam cell formation and atherosclerosis in apolipoprotein E-knockout mice.
    Shiraishi Y, Watanabe T, Suguro T, Nagashima M, Kato R, Hongo S, Itabe H, Miyazaki A, Hirano T, Adachi M.
    J Hypertens; 2008 Oct 25; 26(10):1955-65. PubMed ID: 18806619
    [Abstract] [Full Text] [Related]

  • 6. Effect of macrophage-derived apolipoprotein E on hyperlipidemia and atherosclerosis of LDLR-deficient mice.
    Shi W, Wang X, Wong J, Hedrick CC, Wong H, Castellani LW, Lusis AJ.
    Biochem Biophys Res Commun; 2004 Apr 23; 317(1):223-9. PubMed ID: 15047172
    [Abstract] [Full Text] [Related]

  • 7. Reduced atherosclerotic lesions in P2Y1/apolipoprotein E double-knockout mice: the contribution of non-hematopoietic-derived P2Y1 receptors.
    Hechler B, Freund M, Ravanat C, Magnenat S, Cazenave JP, Gachet C.
    Circulation; 2008 Aug 12; 118(7):754-63. PubMed ID: 18663083
    [Abstract] [Full Text] [Related]

  • 8. Ticlopidine attenuates progression of atherosclerosis in apolipoprotein E and low density lipoprotein receptor double knockout mice.
    Jawien J, Csanyi G, Gajda M, Mateuszuk L, Lomnicka M, Korbut R, Chlopicki S.
    Eur J Pharmacol; 2007 Feb 05; 556(1-3):129-35. PubMed ID: 17174298
    [Abstract] [Full Text] [Related]

  • 9. Antiatherogenic activity of fungal beauveriolides, inhibitors of lipid droplet accumulation in macrophages.
    Namatame I, Tomoda H, Ishibashi S, Omura S.
    Proc Natl Acad Sci U S A; 2004 Jan 20; 101(3):737-42. PubMed ID: 14718664
    [Abstract] [Full Text] [Related]

  • 10. Increased low-density lipoprotein oxidation and impaired high-density lipoprotein antioxidant defense are associated with increased macrophage homing and atherosclerosis in dyslipidemic obese mice: LCAT gene transfer decreases atherosclerosis.
    Mertens A, Verhamme P, Bielicki JK, Phillips MC, Quarck R, Verreth W, Stengel D, Ninio E, Navab M, Mackness B, Mackness M, Holvoet P.
    Circulation; 2003 Apr 01; 107(12):1640-6. PubMed ID: 12668499
    [Abstract] [Full Text] [Related]

  • 11. Effects of probucol on atherosclerosis of apoE-deficient or LDL receptor-deficient mice.
    Yoshikawa T, Shimano H, Chen Z, Ishibashi S, Yamada N.
    Horm Metab Res; 2001 Aug 01; 33(8):472-9. PubMed ID: 11544561
    [Abstract] [Full Text] [Related]

  • 12. Atorvastatin has hypolipidemic and anti-inflammatory effects in apoE/LDL receptor-double-knockout mice.
    Nachtigal P, Pospisilova N, Jamborova G, Pospechova K, Solichova D, Andrys C, Zdansky P, Micuda S, Semecky V.
    Life Sci; 2008 Mar 26; 82(13-14):708-17. PubMed ID: 18289605
    [Abstract] [Full Text] [Related]

  • 13. Naringenin decreases progression of atherosclerosis by improving dyslipidemia in high-fat-fed low-density lipoprotein receptor-null mice.
    Mulvihill EE, Assini JM, Sutherland BG, DiMattia AS, Khami M, Koppes JB, Sawyez CG, Whitman SC, Huff MW.
    Arterioscler Thromb Vasc Biol; 2010 Apr 26; 30(4):742-8. PubMed ID: 20110573
    [Abstract] [Full Text] [Related]

  • 14. Serum amyloid A and lipoprotein retention in murine models of atherosclerosis.
    O'Brien KD, McDonald TO, Kunjathoor V, Eng K, Knopp EA, Lewis K, Lopez R, Kirk EA, Chait A, Wight TN, deBeer FC, LeBoeuf RC.
    Arterioscler Thromb Vasc Biol; 2005 Apr 26; 25(4):785-90. PubMed ID: 15692094
    [Abstract] [Full Text] [Related]

  • 15. FXR deficiency causes reduced atherosclerosis in Ldlr-/- mice.
    Zhang Y, Wang X, Vales C, Lee FY, Lee H, Lusis AJ, Edwards PA.
    Arterioscler Thromb Vasc Biol; 2006 Oct 26; 26(10):2316-21. PubMed ID: 16825595
    [Abstract] [Full Text] [Related]

  • 16. Effect of the ACAT inhibitor, HL-004, on cholesterol metabolism in macrophages.
    Murakami S, Yamagishi I, Asami Y, Sato M, Tomisawa K.
    Cell Mol Biol (Noisy-le-grand); 1996 Sep 26; 42(6):865-72. PubMed ID: 8891354
    [Abstract] [Full Text] [Related]

  • 17. Hepatic expression of apolipoprotein E inhibits progression of atherosclerosis without reducing cholesterol levels in LDL receptor-deficient mice.
    Tsukamoto K, Tangirala RK, Chun S, Usher D, Puré E, Rader DJ.
    Mol Ther; 2000 Feb 26; 1(2):189-94. PubMed ID: 10933930
    [Abstract] [Full Text] [Related]

  • 18. Preferential pharmacological inhibition of macrophage ACAT increases plaque formation in mouse and rabbit models of atherogenesis.
    Perrey S, Legendre C, Matsuura A, Guffroy C, Binet J, Ohbayashi S, Tanaka T, Ortuno JC, Matsukura T, Laugel T, Padovani P, Bellamy F, Edgar AD.
    Atherosclerosis; 2001 Apr 26; 155(2):359-70. PubMed ID: 11254906
    [Abstract] [Full Text] [Related]

  • 19. The effect of montelukast on atherogenesis in apoE/LDLR-double knockout mice.
    Jawien J, Gajda M, Wołkow P, Zurańska J, Olszanecki R, Korbut R.
    J Physiol Pharmacol; 2008 Sep 26; 59(3):633-9. PubMed ID: 18953103
    [Abstract] [Full Text] [Related]

  • 20. Massive xanthomatosis and altered composition of atherosclerotic lesions in hyperlipidemic mice lacking acyl CoA:cholesterol acyltransferase 1.
    Accad M, Smith SJ, Newland DL, Sanan DA, King LE, Linton MF, Fazio S, Farese RV.
    J Clin Invest; 2000 Mar 26; 105(6):711-9. PubMed ID: 10727439
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 42.